Structural Investigations of the Inhibition of Escherichia coli AmpC β-Lactamase by Diazabicyclooctanes
Pauline A. Lang, T.M. Leissing, Malcolm G. P. Page, Christopher J. Schofield, Jürgen Brem
Abstract
β-Lactam antibiotics are presently the most important treatments for infections by pathogenic Escherichia coli , but their use is increasingly compromised by β-lactamases, including the chromosomally encoded class C AmpC serine-β-lactamases (SBLs). The diazabicyclooctane (DBO) avibactam is a potent AmpC inhibitor; the clinical success of avibactam combined with ceftazidime has stimulated efforts to optimize the DBO core.
Topics & Concepts
AvibactamEscherichia coliSerineBeta-Lactamase InhibitorsAntibioticsCeftazidimeEnterobacteriaceaeBiologyEnzymeChemistryMicrobiologyBiochemistryBacteriaGeneticsPseudomonas aeruginosaGeneAntibiotic Resistance in BacteriaAntibiotics Pharmacokinetics and EfficacyPneumocystis jirovecii pneumonia detection and treatment